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410-1 Genetically Determined Resistance to Collagenase 
Action Alters Content of Collagen and Smooth Muscle 
Cells in Atheroma 
Yoshihiro Fukumoto, Peter Libby, Elena Rabkin, Nerea Varo, Koichiro Harada, 
Christopher C. Hill, Patrick R. Lawler, Frederick J. Schoen, Stephen M. Krane, Masanod 
Aikawa, Brigham and Women's Hospital, Boston, Massachusetts. 
We have hypothesized that proteolytic activity produced by activated macrophages con- 
tributes to instability of atheroma, a common trigger of thrombosis causing acute coro- 
nary syndromes such as unstable angina, or myocardial infarction. However, no direct 
evidence links collagenases with regulation of the collagen content of plaques in vivo. 
This study tested the hypothesis that collagenolysis critically influences the structure of 
atheroma in geneticelly-altered mice. We examined collagen accumulation in atheroma 
of apolipoprotein E-deficient mice (apoE-/-) expressing collagenase-rasistant type I col- 
lagen (ColR/R, n=6) or wild-type type I collagen (Col+/+, n=5). Aortic atheroma of both 
groups contained similar amounts of macrophages expressing matrix metalloprotainase- 
13 (MMP-13/collagenase-3, the major collagenase in mice), as determined by quantita- 
tive color image analysis of immunohistochemically stained sections. Cultured peritoneal 
macrophagss from both groups had similar levels of MMP-13/collagenase-3 mRNA and 
secreted protein. Atheroma of ColR/R/apoE-/- mice, however, contained significantly 
more interstitial collagen than those of Col+/+/apoE-/- mice (picrosirius red polarization). 
Atheroma from ColR/R/apoE-/- contained fewer smooth muscle cells (a major source of 
collagen in atheroma). These results show that macrophage-dedved collagenase action 
influences a component of plaque structure critical to the clinical complications of athero- 
sclerosis. 
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2:15 p.m. 
A Novel Inhibitor of _Protein Klnaee-C as a Therapeutic 
for  Ischemic Reperfusion Injury in Acute Coronary 
Syndromes 
Felix Lee, Koichi Inagaki, Leon Chen, Lynn Bailey, Fumi Ikeno, Jennifer Lyons, Donna 
Bouley, Paul Yock, Andrew Carter, Alan Yeung, Dada Mochly-Rosen, Stanford Universi~ 
Stanford, Califomia. 
Objective: Although therapies for acute coronary syndromes (ACS) are directed toward 
timely reperfusion utilizing thrombolytic agents and mechanical interventions, no pharma- 
cological therapies have been developed to protect the myocardium from cellular injury. 
Ischemic preconditioning (IP) is a natural cardioprotective process whereby short periods 
of isshemia enhance the tolerance of the heart to subsequent prolonged isshemia. Pro- 
tein kinase-C (PKC) is thought to play a critical role in the mechanism of IP. We have 
recently developed isozyme-selective 8PKC inhibitor (~V1-1) and previously demon- 
strated inhibition of 5PKC is sufficient o reduce cellular injury in-vitro due to ischemia. 
Therefore, the ability to modulate 8PKC activity in-vivo may allow us to invoke cardiopro- 
tection after an ischemic event has already occurred. Methods: Utilizing truncated HIV-1 
Tat-protein (TAT) to mediate rapid and efficient ransmembrane delivery of peptides, we 
examined the effect of local delivery of TAT-SV1-1 on protection and functional recovery 
from ischemic damage. Utilizing a Langendorff model of ischemic injury (20 min) in rat 
hearts (n=4), delivery of 8V1-1 (50 nM) immediately after injury demonstrated improved 
LVDP (60+/-12% vs 16+/-4%, p<0.00003), reduced LVEDP (56+/-15 vs 107+/-8 mm Hg, 
p<0.01) and reduced CPK release (2170+/-492U vs 5568+/-446U, p<0.0005) compared 
to controls (n=4). Utilizing a clinically relevant model of acute porcine (n=4) coronary 
ischemia (30 minutes) using a balloon catheter inflated in the LAD artery followed by 
local delivery of 8V1-1 (2.5 mM) dudng the final 10 minutes of ischemia preserved LV 
EF% 55+/-1% vs 43+/-2%, p<0.0005), reduced hypokinetic areas of the heart (10+/-1% 
vs 31+/-8%, p<O.02) and reduced infarct size (14%+/-5 vs 34%+/-3, p<0.008) by histo- 
morphometry, versus controls (n=5). Conclusion: Myocardial function preservation and 
reduced infarct size can be effected by locally delivering a cardioprotective peptide (8Vl- 
1) in a clinically relevant model, after the ischemic event. 
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2:30 p.m. 
410-3 Isolation, Expansion, and Genetic Modification of Bone 
Marrow Meeenchymel Stem Cells for In-Vivo Repair of 
Damaged Myocardlum 
Abeel A. Manoi, Victor J. Dzau, Brigham and Women's Hospital and Harvard Medical 
School, Boston, Massachusetts. 
Several groups have reported the use of unfractionated or cell sorted bone marrow 
derived cells for cardiac repair. The characterization, expansion and conditions for differ- 
entiation of these cells need further definition. Here, we describe the isolation, character- 
ization, and propagation of CD34-/c-kit+ subpopulatioc of mssechymal stem cells 
derived from adult bone marrow which can differentiate into cardiac myocytes, and be 
transduced to stably express a reporter gene. These cells can induce a gain of cardiac 
function when transplanted into the myocardium damaged by ischemic injury. The mono- 
nuclear fraction of whole bone marrow from adult Sprague Dawley rats was separated by 
density centdfugation. Bone marrow stromal cells attached preferentially to uncoated 
plastic surfaces, and proliferated in mixed culture with hematopoietic ells (HCs) under 
standard conditions. MSCs were retrovirally transduced with green fluorescent protein 
(GFP) or Lac Z with over 80% transduction efficiency. MSCs express connexin 43 and c- 
kit (CDl17) but do not express hematopoietic markers CD34, CD45, CD11b; or mature 
cardiac markers such as troponin, myosin heavy chain or desmin at this stage. MSCs 
can be separated from HCs by negative immuno-magnetic bead sorting, but cease to 
proliferate after cell sorting. In separate studies, we have shown that in the presence of 
5-azacytidine, MSCs can differentiate into cardiac myocytes as evidenced by the pres- 
ence of myocyte specific markers by immunostaining and RT-PCR. Lac Z transduced 
MSCs are injected into the border zone of the ischemic myocerdium 60 minutes after 
ligation of the rat LAD. Two weeks later, the free wall and apex of the left ventricle exhibit 
extensive blue staining by beta-galactosidase staining, suggesting the presence of Lac-Z 
expressing ceils. Echocardiographic analysis reveals a statistically significant 54% 
increase in fractional shortening when compared to control, and a 34% increase in ejec- 
tion fraction. This strategy suggests that bone marrow derived MSCs can be expanded to 
sufficient scale ex vivo, and genetically engineered to treat damaged myocerdium. 
2:45 p.m. 
410-4 Mesenchymel Stem Cell Injection Induces Cardiac 
Nerve Sprouting and Tenescin Expression in a Swine 
Model of Myocardial Infarction 
Hui-Nam Pak. Mohammed Qayyum, Angela C. Lai, Dave T. Kim, Akira Hamabe, Yasushi 
Miyauchi, Michael C. Lill, Kaname Takizawa, Michael C. Fishbein, Behrooz G. Sharifi, 
Peng-Sheng Chen, Raj Makkar, Cedars-Sinai Medical Center, Los Angeles, California. 
UCLA, Los Angeles, California. 
Background - Mesenchymal Stem Cell (MSC) injection into the myocardium is a promis- 
ing technique to improve cardiac hemodynarnic performance. Whether or not MSC injec- 
tion can result in cardiac nerve sprouting in unclear. 
Methods and Results - We created anterior waft myocardial infarction by intraluminal 
micro-coil embolization of distal left anterior descending coronary artery in 16 swine. One 
month later, 6 swine were given MSC and fresh bone marrow (BM) into infarcted myocar- 
dium (MSC group). Four swine were given fresh bone marrow only (BM group) and 6 
swine were given culture media (MI-only group). The swine were sacrificed 95.8+3.5 
days after MI. Six normal swine were used as control Atrial and ventricutar tissues were 
sampled for immunocytochemical studies using antibodies against growth-associated 
protein 43 (GAP43), tyrosine hydroxylase (TH) and 3 subtypes of tenascin (TnR, C and 
X). Five fields per slide were counted for nerve density. The results show 1) there were 
more GAP43-positive nerves in MSC group (117.4±54.9/mm 2) than in BM group 
(42.7.+.22.2/mm2), MI-only group (56.0~_35.8/mm2), or Control (24.3+~5.6/mm 2) 
(p<0.0001). TH staining also showed higher nerve densities in MSC group (26.9+_27.2/ 
mm 2) than in MI-only group (15.7_+t7.3/mm 2, p<0.05) or Control (2.6±1.1/mm 2, 
p<0.0001). 2) There were more sympathetic (TH positive) nerves in myocardium distant 
from infarct than in the peri-infarct area (17.0-~18.3/mm 2 vs 6.0!-_4.g/ram 2, p<0.05). 3) 
Optical intensity and color analyses using Image-Pro plus 4.0 software showed a signifi- 
cantly higher TnR and TnC expression in MBC group or BM group than in MI-only group 
or Control (p<0.001). 
Conclusions - MBC injection into one-month old myocardial infarct results in over 
expression of cardiac TnR, TnC, and significant cardiac nerve sprouting, resulting in 
sympathetic hypednnervation. 
3:00 p.m. 
410-5 Familial Restrictive Cardiomyopathy Caused by a 
Missense Mutation in the Desmin Gene: Possible Role 
of Apoptosis in Disease Pathogenesis 
Zaev Pedes. Nell E. Bowles, Matted Vatta, Shinawe Jimenez, Jacqueline Bzmuszkovicz, 
Yassemi Capetanaki, Jeffrey A. Towbin, Baylor College of Medicine, Houston, Texas, 
Children's Hospital of Los Angeles, Los Angeles, Califomia. 
Background: RCM is characterized by diastolic ventricular dysfunction with preservation 
of systolic function and left ventricular end-diastolic dimension and thickness. Amyloid 
and desmin accumulation are common. Mutations in transthyretin have been shown to 
cause inherited forms of amyloidosis associated with cardiomyopathy, while mutations in 
the desmin gene have been found in patients with RCM or dilated cardiomyopathy. 
Methods: The desmin and transthyretin genes of patients with isolated RCM (2 families 
and 11 patients with sporadic disease) were screened for mutations by denaturing high 
performance liquid chromatography and DNA sequencing. Complementary DNA clones 
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were prepared in a eukaryotic expression vector and expressed in cultured cells by tran- 
sient transfection, in the presence or absence of actinomycin D. 
Results: No mutations were identified in the transthyretin gene. A C to T substitution of 
nucleotide 635 of desrnin, resulting in the replacement of alanine 212 by valine (A212V) 
was identified in one family with isolated RCM. Expression of the wild type and mutant 
proteins in cultured myocytes showed no difference in the desmin'filamentous network. 
However, exposure of these cells to actinomycin D resulted in increased filament disar- 
ray and cell death in cells expressing A212V desmin. 
Conclusions: Here we describe a novel mutation in the deamin gene in a family with 
RCM The increased susceptibility of mycoytes expressing this mutation to actinomycin- 
induced cell death suggest a possible role of apoptosis in the pathologic events leading 
to RCM. 
ORAL CONTRIBUTIONS 
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Georgia World Congress Center, Room 255W 
2:00 p.m. 
827-1 Does the Evidence Support the Verdict of High Profile 
Clinical Trials? A Conventional Versus Bayesian 
Perspective 
Saniav Kaul. Matthew J. Price, Sdram Padmanabhan, Vladimir Rukshin, George A. 
Diamond, Cedars Sinai Medical Center, Los Angeles, Cafifornia, UCLA School of 
Medicine, Los Angeles, Califomia. 
Background: Conventional significance tests frequently characterize clinically negligible 
differences as being 'statistically signiticant'~ Objective: To perform a Bayesian analysis 
of clinical trials and compare it with the conventional two-sided p value. Methods: Seven 
high profile trials (those having a major impact on CAD treatment) reported in the last 5 
years were identified for analysis. Results are expressed in odds ratio (OR) and associ- 
ated 95% confidence interval (CI), two-sided p value (using a chi square test), number 
needed to treat (NNT) to avoid 1 event (the inverse of the absolute risk reduction), prob- 
ability of benefit (pb) based on Bayesian analysis, and adjusted NNT (NNT/pb). Results: 
The results of the 2 analyses were discordant (p<0.05 and Pb<95%) in 5 and concordant 
(p<0.05 and Pb>95%) in 2 out of 7 trials. The probability of benefit in the discordant trials 
was low ranging from 7% for clopidogrel in CAPRIE to 30% for carvedilol in CAPRICORN 
despite statistically significant odds ratios and p values. The corresponding adjusted 
NNT values increased from a range of 29-115 to 94-3833. Conclusions: The conven- 
tional p value threshold is too liberal and does not correspond with Bayesian threshold of 
>95% probability. Investigators should rely on Bayesian analyses to safeguard against 
such errors leading to inappropriate claims. Alternatively, a more stringent conventional p 
value threshold, e.~]., <0.01 to <0.001 should be chosen. 0 
Trial N Endpoint OR (95% p NNT pb Adjusted 
CI) value NNT 10 
CAPRIE (CIopidogrel in 19413 Death, MI or 0.91 0.047 115 0.07 3833 16 
Vascular disease) stroke @ 1-3y (0.83,1.00) 20 
EP;STENT(Abciximabin 1603 Death @ ly 0.42 0.037 75 0.12 625 25 
Coronary Stenting) (0.18,0.97) 
3O 
ESSENCE + TIMI-11B 7081 Death or MI @ 0.79 0.016 75 0.20 375 
(Enoxapadn in Acute 14d (0.69,0.90) 35 
Coronary Syndrome 40 
MIRACL (Atorvastatinin 3086 Death, MI or 0.83 0.048 39 0.16 218 45 Acute Coronary Syndrome) ischemia @ 4m (0.68,1.00) 
CAPRICORN (Carvedilolin 1959 Death @ 1.3y 0.74 0.026 29 0.31 94 50 
Post-MI LV Dysfunction) (0.57,0.97) 
HOPE (Ramipril in 9297 Death, MI or 0.75 <0.001 27 >0.99 27 
Seccnary Prevention of stroke @ 5y (0.68,0.84) 
CVD) 
Lyon Diet Heart Study 423 Death or MI @ 0.25 <0.001 7 >0.99 7 
(Mediterranean Diet for 46m (0.13,0.47) 
Secondary Prevention) 
2:15 p.m. 
827-2 Do Glycoproteln 2B3A Inhibitore Reduce Morta l i ty?  A 
Bayes ian  Meta-Ana lys ls  
Saniav Kaul, Matthew J. Price, Briram Padmanabhan, Vladimir Rukshin, George A. 
Diamond, Cedars Sinai Medical Center, Los Angeles, California, UCLA School of 
Medicine, Los Angeles, California. 
Background: Although nearly 50000 patients have been enrolled in clinical trials of gly- 
coprotein 2b3a inhibitors (GPIs), the issue of their effect on cardiac mortality remains 
controversial, in part, because conventional tests of statistical significance are unreliable 
when applied to such large samples. Oblectlve: To perform a Bayesian meta-analysis of 
the effect of GPIs on total mortality, and compare the resultant probability of benefit with 
the conventional p value. Methods: A total of 20 randomized trials involving 48584 
patients were identified for analysis at 30 d and 5 trials involving 10959 patients for anal- 
ysis at 1 year. Pooled trial results are expressed in terms of the odds ratio (OR) and 
associated 95% confidence interval (CI), the two-sided p value (using a chi square test), 
the probability of benefit (10b) based on Bayesian analysis, and number needed to treat 
(NNT) to avoid 1 mortality (the inverse of the absolute risk reduction). Results: At 30 
days, there were 672 deaths among 27073 GPI and 590 deaths among 21511 placebo 
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patients [OR = 0.90 (0.81, 1.01), p = 0.08, Pb = 0.02, NNT = 384]. At 1 year, there were 
251 deaths among 6729 GPI and 183 deaths among 4230 placebo patients [OR = 0.86 
(0.71, 1.04), p = 0.12, Pb = 0.03, NNT = 168]. Thus, the probability that GPI therapy 
reduced total mortality was very low (2% at 30 days and 3% at 1 year) despite odds 
ratios and p values that tended toward statistical significance. Four tdals of abciximab 
were analyzed separately (EPIC, EPILOG, EPISTENT, CADILLAC). At 1 year, there 
were 127 deaths among 5205 abciximab and 118 deaths among 3472 placebo patients 
[OR = 0.72 (0.56, 0.93), p = 0.01, Pb = 0.19, NNT = 108]. The best conventional estimate 
was a 0.93% absolute reduction in mortality with abciximab among 8677 patients. How- 
ever, there was only a 19% probability that abciximab was superior to placebo despite 
conventional statistical significance. Conclusion: The widespread belief that GPIs, spe- 
cifically abciximab, confer a significant mortality benefit is directly controverted by this 
Bayesian meta-analysis. Future large-scale clinical trials should incorporate the Baye- 
sian approach in their design and analysis in order to minimize the potential for such 
errors. 
2:30 p.m. 
827-3 Cost -E f fect iveness  of Prophylactic Amiodarone 
Therapy for the Prevention of Atrial Fibrillation in 
Patients Undergoing Cardiac Surgery Varies by 
Underlying Risk and "l~pe of Surgery: Results for 
CABG, Valve Replacement, and Combined CABG and 
Valve Replacement 
Elizabeth M. Mahonev, Jovonne K. Williams, Emir Veledar, Trevor D. Thompson, William 
S. Weintraub, Emory University School of Medicine, Atlanta, Georgia. 
Background. The selection of patients (Lots) for whom prophylactic amiodarone therapy to 
prevent atrial fibrillation (AF) following cardiac surgery is cost-effective (CE) is difficult. 
This study adds to previous efforts by separately examining the risk and added costs of 
AF in CABG, valve replacement (VR) and combined CABG and VR (CABG+VR) pts. 
Methods. Outcomes and costs for 8709 CABG, 1217 VR and 624 CABG+VR pts at 
Emory University Hospitals from 1/94-6/99 were used to examine the CE of targeted ami- 
odarone therapy for each of the three types of surgical patients. Logistic regression was 
used to develop models for the prediction of AF and linear regression was used to predict 
hospital costs, including the additional costs attributed to AF. Predicted probabilities from 
the logistic models were used as the index from which to identify patient subsets to be 
targeted for therapy. Marginal CE of targeting therapy to subsets at incrementally lower 
levels of risk was evaluated. CE was evaluated as cost/episode of AF averted. Effective- 
ness of amiodarone was assumed to be 26% (ARCH trial) and cost $973 (7 amps/day for 
2 days at $69.50/amp). 
Results. AF rates were 17.7% for CABG, 24.6% for VR and 33.8% for CABG+VR. 
Treatment CABG: CABG: VR: VR: CABG+VR: CABG+VR: 
Threshold: % treated marginal % treated marginal % treated marginal 
Probability of AF cost/AF cost/AF cost/AF 
averted averted averted 
100 $55,854 100 $43,011 100 $39,698 
77.7 $34,087 91.7 $27,061 99.0 $22,009 
55.5 $25,224 78.0 $18,658 95.4 $14,325 
36.4 $20,540 60.6 $13,687 88.6 $9,903 
21.3 $17,479 44.6 $10,603 76.0 $7,178 
10.6 $15,406 32.2 $8,626 63.8 $4,947 
4.2 $13,864 19.1  $7,179 42.6 $3,430 
1.5 $12,696 9.1 $5,990 27.9 $2,346 
0.5 $11,789 3.5 • $5,089 14.4 $1,423 
0.1 1.1 -- 9.3 -- 
Conclusions: Using $5000 as an acceptable cost/AF averted, prophylactic amiodarone 
use in CABG pts is not cost-effective. Therapy would be recommended for a small frac- 
tion of VR pts who have a predicted risk of AF>45% and roughly 2/3 of CABG+VR pts 
who have a predicted risk of AF>30%. Nomograms can help identify these pts. 
2:45 p.m. 
827-4 The Intermountaln Risk Model :  Predict ing Morta l i ty  by 
Traditional and Novel Risk Factors Among Patients With 
Sign i f icant  Coronary  Disease 
Beniamin D. Home, Joseph B. Muhlestain, Chloe A. Allen Maycock, John F. Carlquist, 
Donald L. Lappe', Robert R. Pearson, Dale G. Renlund, Jeffrey L. Anderson, LDS 
Hospital, Salt Lake City, Utah, University of Utah, Salt Lake Ci~ Utah. 
Background: Although treatment guidelines exist for guiding the therapy of patients with 
diagnosed coronary artery disease (CAD), they are largely based on risk models that 
predict CAD onset, not mortality after disease has developed. No mortality risk model 
has been created with data from the general CAD patient population. This study evalu- 
ated predictive risk models for mortality among patients with significant, angiographically- 
defined CAD. 
Methods: The catheterization registry of the Intermountain Heart Collaborative Study 
provided a cohort of 2,585 patients with significant, angiographically-proven CAD (>_1 
lesion of ->70% stenosis). At angiography, 16 traditional and 3 novel (C-reactive protein 
[CRP], cytomegalovirus [CMV], homocysteine [HCY]) risk factors were measured. 
Patients were followed for 2.4±1.6 years (maximum: 5.8 years) to determine the inci- 
dence of mortality. 
Results: Average age was 65±11 years, 76% were male, and 250 (9.7%) died. Prsdic- 
